Fludarabine, cyclophosphamide and rituximab (FCR) has been the standard of care for first‐line chronic lymphocytic leukemia (CLL) treatment for more than a decade and the latest European Society for Medical Oncology guidelines still consider FCR a therapeutic option for immunoglobulin heavy‐chain variable region gene (IGHV) mutated patients devoid of TP53 disruption. Exploiting a multicenter, real‐life cohort of CLL patients treated with FCR, we previously showed that IGHV mutated patients devoid of TP53 abnormalities and of 11q deletion can achieve a durable remission.8 In the present study, we updated the follow‐up of 301 CLL patients derived from the initial cohort.
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia
Perbellini, Omar;Ferrarini, Isacco;Visco, Carlo;Rossi, Davide;
2022-01-01
Abstract
Fludarabine, cyclophosphamide and rituximab (FCR) has been the standard of care for first‐line chronic lymphocytic leukemia (CLL) treatment for more than a decade and the latest European Society for Medical Oncology guidelines still consider FCR a therapeutic option for immunoglobulin heavy‐chain variable region gene (IGHV) mutated patients devoid of TP53 disruption. Exploiting a multicenter, real‐life cohort of CLL patients treated with FCR, we previously showed that IGHV mutated patients devoid of TP53 abnormalities and of 11q deletion can achieve a durable remission.8 In the present study, we updated the follow‐up of 301 CLL patients derived from the initial cohort.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Hematological Oncology - 2022 - Moia - Long%E2%80%90term benefit of IGHV mutated patients in a real%E2%80%90life multicenter cohort of.pdf
solo utenti autorizzati
Tipologia:
Documento in Pre-print
Licenza:
Creative commons
Dimensione
552.39 kB
Formato
Adobe PDF
|
552.39 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
